CY1119093T1 - Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο - Google Patents

Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο

Info

Publication number
CY1119093T1
CY1119093T1 CY20171100455T CY171100455T CY1119093T1 CY 1119093 T1 CY1119093 T1 CY 1119093T1 CY 20171100455 T CY20171100455 T CY 20171100455T CY 171100455 T CY171100455 T CY 171100455T CY 1119093 T1 CY1119093 T1 CY 1119093T1
Authority
CY
Cyprus
Prior art keywords
imp
progenitor
cell
immune regulatory
regulatory
Prior art date
Application number
CY20171100455T
Other languages
Greek (el)
English (en)
Inventor
Ajan Reginald
Martin John Evans
Sabena Sultan
Original Assignee
Cell Therapy Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy Limited filed Critical Cell Therapy Limited
Publication of CY1119093T1 publication Critical patent/CY1119093T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0633—Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
CY20171100455T 2014-06-12 2017-04-24 Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο CY1119093T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1410504.3A GB201410504D0 (en) 2014-06-12 2014-06-12 Immuno-modulaltory progenitor (IMP) cell
PCT/GB2015/051673 WO2015189587A1 (en) 2014-06-12 2015-06-09 Immuno-modulatory progenitor (imp) cell

Publications (1)

Publication Number Publication Date
CY1119093T1 true CY1119093T1 (el) 2018-01-10

Family

ID=51266501

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100455T CY1119093T1 (el) 2014-06-12 2017-04-24 Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο

Country Status (23)

Country Link
US (2) US12029763B2 (https=)
EP (2) EP3211069A1 (https=)
JP (2) JP6185657B2 (https=)
KR (2) KR20160029092A (https=)
CN (1) CN105473711A (https=)
AU (1) AU2015273271B2 (https=)
CA (1) CA2951492C (https=)
CY (1) CY1119093T1 (https=)
DK (1) DK2984163T3 (https=)
EA (1) EA034083B1 (https=)
ES (1) ES2622397T3 (https=)
GB (1) GB201410504D0 (https=)
HR (1) HRP20170657T1 (https=)
HU (1) HUE033392T2 (https=)
IL (2) IL249298B (https=)
LT (1) LT2984163T (https=)
MA (1) MA38860B1 (https=)
MY (1) MY181994A (https=)
PL (1) PL2984163T3 (https=)
PT (1) PT2984163T (https=)
SG (1) SG11201610355PA (https=)
WO (1) WO2015189587A1 (https=)
ZA (1) ZA201608402B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201513996D0 (en) * 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
WO2017168170A1 (en) * 2016-03-31 2017-10-05 Cell Therapy Limited Immuno-modulatory progenitor (imp) cell expressing one or more of cd3, cd3e, cd8, cd8b, cd4, cd5, cd6 and cd7
US11179420B2 (en) * 2016-04-27 2021-11-23 Rohto Pharmaceutical Co., Ltd. Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject
CN106267161A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种干细胞制剂及其制备方法和应用
CN107184602B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
US11773376B2 (en) 2017-07-13 2023-10-03 National University Corporation Tokyo Medical And Dental University Artificial tendon or ligament tissue produced using three-dimensional mechanosignaling cell culture system
CA3069805A1 (en) * 2017-07-14 2019-01-17 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
CN108660203A (zh) * 2018-05-18 2018-10-16 大连医科大学附属第医院 Cxcr2基因在心脏相关疾病中的用途
WO2019231247A1 (ko) * 2018-05-30 2019-12-05 주식회사 지놈앤컴퍼니 Cd300e 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
US20210228637A1 (en) * 2018-06-05 2021-07-29 Medipost Co., Ltd Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3911733B1 (en) * 2019-01-15 2024-08-21 Cell Therapy Limited Mesodermal killer (mk) cell
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
CN110314173A (zh) * 2019-07-17 2019-10-11 中国医科大学附属第一医院 一种用于治疗骨关节炎的细胞制剂及其制备方法
WO2021092564A1 (en) * 2019-11-07 2021-05-14 Massachusetts Eye And Ear Infirmary Cultivated autologous limbal epithelial cell (calec) transplantation
CN116482350B (zh) * 2022-01-17 2025-10-21 上海源奇生物医药科技有限公司 用于监测急性b淋巴细胞白血病微小残留病灶的流式细胞术试剂盒及监测方法
WO2024080661A1 (ko) * 2022-10-12 2024-04-18 (주) 엘피스셀테라퓨틱스 신규한 혈관 형성 줄기세포
CN120379687A (zh) * 2022-10-14 2025-07-25 爱尔兰国立科克大学 胎盘表达的蛋白用于治疗肌腱损伤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
WO2011053860A2 (en) 2009-10-30 2011-05-05 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
EP2506867B1 (en) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
US20130189741A1 (en) * 2009-12-07 2013-07-25 Cellscript, Inc. Compositions and methods for reprogramming mammalian cells
WO2012052911A1 (en) 2010-10-22 2012-04-26 Nokia Corporation Method and apparatus for co-operative reception for network controlled device to device
CN104508124B (zh) * 2011-07-06 2017-11-17 细胞治疗有限公司 中胚层谱系祖细胞
TR201908716T4 (tr) 2011-11-23 2019-07-22 Cell Therapy Ltd Platelet lizat jeli.
US9682104B2 (en) * 2012-01-26 2017-06-20 Jadi Cell Llc Lyophilized platelet lysates
US9670457B2 (en) 2012-05-08 2017-06-06 Stem Cell Reserve Lp Stem cells and matrix from cord tissue

Also Published As

Publication number Publication date
DK2984163T3 (en) 2017-05-08
EA201692254A1 (ru) 2017-06-30
MA38860B1 (fr) 2017-09-29
HUE033392T2 (en) 2017-12-28
HK1219504A1 (en) 2017-04-07
IL249298B (en) 2018-11-29
JP2016525342A (ja) 2016-08-25
KR20180004319A (ko) 2018-01-10
US20190142869A1 (en) 2019-05-16
KR20160029092A (ko) 2016-03-14
ES2622397T3 (es) 2017-07-06
MY181994A (en) 2021-01-18
HRP20170657T1 (hr) 2017-06-30
LT2984163T (lt) 2017-05-10
EA034083B1 (ru) 2019-12-25
AU2015273271A1 (en) 2016-12-22
AU2015273271B2 (en) 2020-12-17
PL2984163T3 (pl) 2017-08-31
CA2951492A1 (en) 2015-12-17
CN105473711A (zh) 2016-04-06
GB201410504D0 (en) 2014-07-30
JP6185657B2 (ja) 2017-08-23
ZA201608402B (en) 2019-04-24
EP2984163B1 (en) 2017-02-01
SG11201610355PA (en) 2017-01-27
CA2951492C (en) 2022-12-06
WO2015189587A1 (en) 2015-12-17
JP2017200474A (ja) 2017-11-09
US20170080029A1 (en) 2017-03-23
MA38860A (fr) 2016-02-17
NZ727129A (en) 2021-02-26
EP3211069A1 (en) 2017-08-30
PT2984163T (pt) 2017-05-09
EP2984163A1 (en) 2016-02-17
IL249298A0 (en) 2017-02-28
IL262827A (en) 2018-12-31
US12029763B2 (en) 2024-07-09

Similar Documents

Publication Publication Date Title
CY1119093T1 (el) Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
IL269440B (en) Closed systems for use in selecting immune cell populations for adoptive therapy
EP3707248A4 (en) MODIFIED IMMUNE CELLS AND THEIR USES
EP3562492A4 (en) GENETICALLY MODIFIED NATURAL KILLER CELLS
IL261621A (en) Genome edited immune effector cells
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
IL258666A (en) Natural killer cells and ilc3 cells and uses thereof
IL262359A (en) Ex vivo bite-activated t cells
IL247460A0 (en) Viral resistant cells and uses thereof
DK3434762T3 (da) Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
IL249970B (en) Gamma delta t cells and uses thereof
TN2016000008A1 (en) Electrical energy storage and discharge system
CY1122701T1 (el) Απελευθερωση πρωτεϊνης με βαση βακτηρια
DK3256468T3 (da) Tricykliske forbindelser og anvendelser deraf i lægemidler
EP3565889A4 (en) CD96 / TIGIT GENETICALLY MODIFIED REDUCED EXPRESSION NK-92 CELLS
PL3322425T3 (pl) Zmodyfikowane genetycznie, skierowane przeciwko osobie trzeciej centralne limfocyty T pamięci i ich zastosowanie w immunoterapii
HRP20190028T1 (hr) Interleukin-2 fuzijski proteini i njihove primjene
EP3507302A4 (en) CONDITIONS ACTIVE POLYPEPTIDES AND METHOD FOR THE PRODUCTION THEREOF
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
IL259202A (en) Modified immune cells and uses thereof
IL254389A0 (en) Conjugates of an il-7 moiety and an polymer
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
DK3131577T3 (da) Modificerede værtsceller og anvendelser deraf